A$0.069 -0.0 -1.4%
Last Trade - 26/02/21
| Market Cap | ÂŁ27.2m |
| Enterprise Value | ÂŁ22.9m |
| Revenue | ÂŁ451k |
| Position in Universe | 1086th / 1832 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.67 | 1.55 | 1.66 | 1.62 | 1.07 | 0.80 | -13.6% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The Company is focused on the ongoing clinical development of its antiviral platform. The Company's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The Company has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The Company designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | February 23, 1999 |
| Public Since | January 24, 2001 |
| No. of Shareholders: | 7,632 |
| No. of Employees: | 4 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 701,932,713 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Suite 33 56 Delhi Road, NORTH RYDE, 2113, Australia |
| Web | http://www.biotron.com.au/ |
| Phone | +61 2 98050488 |
| Contact | () |
| Auditors | KPMG |
As of 26/02/21, shares in Biotron are trading at A$0.069, giving the company a market capitalisation of ÂŁ27.2m. This share price information is delayed by 15 minutes.
Shares in Biotron are currently trading at A$0.069 and the price has moved by -40% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biotron price has moved by -41.76% over the past year.
There are no analysts currently covering Biotron.
Biotron is scheduled to issue upcoming financial results on the following dates:
Biotron does not currently pay a dividend.
Biotron does not currently pay a dividend.
Biotron does not currently pay a dividend.
To buy shares in Biotron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biotron are currently trading at A$0.069, giving the company a market capitalisation of ÂŁ27.2m.
Here are the trading details for Biotron:
Based on an overall assessment of its quality, value and momentum, Biotron is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Biotron.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotron. Over the past six months, the relative strength of its shares against the market has been -33.23%. At the current price of A$0.069, shares in Biotron are trading at -21.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biotron.
Biotron's management team is headed by:
Here are the top five shareholders of Biotron based on the size of their shareholding:
